- Home
- GECC vs QNCX Comparison
GECC vs QNCX Comparison
Compare GECC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- QNCX
- Stock Information
- Founded
- GECC 2016
- QNCX 2012
- Country
- GECC United States
- QNCX United States
- Employees
- GECC N/A
- QNCX N/A
- Industry
- GECC Finance: Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- QNCX Health Care
- Exchange
- GECC Nasdaq
- QNCX Nasdaq
- Market Cap
- GECC 106.1M
- QNCX 92.3M
- IPO Year
- GECC N/A
- QNCX 2019
- Fundamental
- Price
- GECC $10.34
- QNCX $1.79
- Analyst Decision
- GECC
- QNCX Strong Buy
- Analyst Count
- GECC 0
- QNCX 4
- Target Price
- GECC N/A
- QNCX $9.50
- AVG Volume (30 Days)
- GECC 28.3K
- QNCX 280.9K
- Earning Date
- GECC 10-31-2024
- QNCX 11-13-2024
- Dividend Yield
- GECC 13.47%
- QNCX N/A
- EPS Growth
- GECC N/A
- QNCX N/A
- EPS
- GECC 0.65
- QNCX N/A
- Revenue
- GECC $39,468,000.00
- QNCX N/A
- Revenue This Year
- GECC $18.56
- QNCX N/A
- Revenue Next Year
- GECC $5.85
- QNCX N/A
- P/E Ratio
- GECC $15.97
- QNCX N/A
- Revenue Growth
- GECC 16.86
- QNCX N/A
- 52 Week Low
- GECC $9.55
- QNCX $0.51
- 52 Week High
- GECC $11.31
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- GECC 57.69
- QNCX 45.75
- Support Level
- GECC $9.96
- QNCX $1.80
- Resistance Level
- GECC $10.74
- QNCX $2.00
- Average True Range (ATR)
- GECC 0.24
- QNCX 0.21
- MACD
- GECC 0.00
- QNCX -0.06
- Stochastic Oscillator
- GECC 76.86
- QNCX 8.14
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.